Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2016-08-29 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Final Cancer Vaccine Doses Delivered to GMP Depot 1
Regulatory Filings Classification · 95% confidence The document is a company announcement about the delivery of final cancer vaccine doses to a GMP depot, describing a milestone in the clinical trial preparation. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or financial reports, and no legal or merger information. The document is relatively short (3435 characters) and reads as a press release or operational update rather than a formal report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an operational update about clinical trial logistics and manufacturing milestones, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2016-08-29 English
Preliminary Final Report 23 pages 127.6KB
Annual Report Classification · 95% confidence The document is titled 'Imugene Limited Appendix 4E' and covers the year ended 30 June 2016. It includes detailed financial results such as revenue, EBIT, net profit after tax, net tangible assets, and loss per share. It also contains a review of operations and activities, including clinical trial updates, manufacturing details, preclinical work, and management changes. The document includes financial statements like the statement of profit or loss, statement of financial position, changes in equity, cash flows, and notes to the financial statements. It mentions that the accounts are in the process of being audited and that an annual report containing the audit report will be provided later. The length of the document (15,000 characters) and the presence of substantive financial data and analysis indicate this is a comprehensive financial report for a full fiscal year. The document is not merely an announcement or a certification but contains actual financial statements and management discussion. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2016
2016-08-29 English
Imugene Receives Approval to Start Gastric Cancer Study 2 pages 174.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Imugene has received approval from the Research Ethics Committee in Thailand to commence site activation for a clinical study of its HER-Vaxx therapy in gastric cancer. It discusses the study phases, patient enrollment plans, and provides background on the company and its product. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a clinical trial approval and site activation, not a financial report, management change, or shareholder meeting material. It is also relatively short (4200 characters) and does not contain any financial or governance information. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2016-08-21 English
Imugene Receives Institutional Review Board approval 2 pages 45.2KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Imugene has received Institutional Review Board approval for a Phase 1b/2 clinical study of its HER-Vaxx therapy in gastric cancer. It discusses the study design, investigators, and trial details but does not contain any financial data, earnings, or regulatory filings. There is no indication that this is a financial report, earnings release, or regulatory filing. It is an update on clinical trial progress and approvals, which does not fit into any financial report categories. The closest relevant category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2016-08-10 English
Appendix 4C - quarterly 5 pages 381.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including cash flow statements, payments to directors, financing activities, and reconciliation of cash. It covers the quarter ended 30th June 2016 and includes substantive financial data and analysis. The document is approximately 7,105 characters long, which is sufficient to contain a full quarterly report rather than just an announcement. The Appendix 4C is a standard Australian Securities Exchange (ASX) form used for quarterly reporting by entities admitted on the basis of commitments, which aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q4 2016
2016-07-28 English
Imugene Receives Institutional Review Board Approval 2 pages 270.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Imugene has received Institutional Review Board approval for a Phase 1b/2 clinical study of its HER-Vaxx therapy in gastric cancer. It discusses the study design, investigators, and significance of the approval. There is no financial data, no regulatory filing references, no shareholder information, no management or board changes, no earnings or capital updates, and no mention of any report being attached or published. The content is primarily a corporate announcement about clinical trial approval, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other categories.
2016-07-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.